Breast Cancer Clinical Trials

• The participant or a legally authorized representative must provide study-specific informed consent prior to pre-entry and, for participants treated in the U.S., authorization permitting release of personal health information.

• The participant must have been greater than or equal to 18 or less than or equal to 50 years of age at the time of breast cancer diagnosis.

• The participant must have a first-time diagnosis of non-metastatic breast cancer which is Stage 0, I, II, or III.

• The participant must have a score of greater than or equal to 5 and less than or equal to 14 on the Patient Health Questionnaire-8 item (PHQ-8).

• Participants must have completed all primary breast cancer treatments at least 6 months prior to and no more than 5 years prior to registration. Note: Primary treatments include surgery, radiation therapy, adjuvant chemotherapy, targeted therapies (e.g., PARP (poly-ADP ribose polymerase) inhibitors, CDK4/6 inhibitors, TDM-1, pertuzumab, or immunotherapy). (Participants may still be taking adjuvant therapy with trastuzumab or adjuvant endocrine therapy or completing minor reconstructive surgery.)

• Participant must be able to understand, speak, read, and write in English or Spanish.

• Participant must be willing to participate in a 6-week program to receive training in mindfulness.

• Participant must be able to use a smartphone, tablet, or other digital device.

• Sex assigned at birth must be female.